Get the Stockscreener App
3.62
4.32%
0.15
Pre-market:
3.59
-0.03
-0.83%
Curevac N V Stock (CVAC) Latest News
Analysts Offer Valuable Insight On CureVac N.V (CVAC) - Stocksregister
CureVac (NASDAQ:CVAC) Shares Gap Up – Should You Buy? - Defense World
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK - ACCESS Newswire
Geode Capital Management LLC Acquires 22,491 Shares of CureVac (NASDAQ:CVAC) - Defense World
UBS Group Lowers CureVac (NASDAQ:CVAC) Price Target to $12.00 - Defense World
CVAC (CureVac N.V) has impressive results - uspostnews.com
CureVac N.V. (NASDAQ:CVAC) Shares Fly 31% But Investors Aren't Buying For Growth - simplywall.st
Legal & General Group Plc Has $359,000 Holdings in CureVac (NASDAQ:CVAC) - Defense World
Understanding the Risks of Investing in CureVac N.V (CVAC) - knoxdaily.com
CureVac (CVAC) Target Price Reduced by UBS Analyst | CVAC Stock News - GuruFocus
UBS Trims Price Target on CureVac to $12 From $13, Maintains Buy Rating - marketscreener.com
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet - ACCESS Newswire
CureVac N.V (CVAC) Stock: Navigating a Year of Stock Volatility - investchronicle.com
CureVac (NASDAQ:CVAC) Shares Gap Up – Here’s Why - Defense World
Can you still get a good price for CureVac N.V (CVAC) Shares at this point? - uspostnews.com
CureVac (CVAC) to Release Quarterly Earnings on Wednesday - Defense World
CureVac Among 3 Promising Penny Stocks To Watch - Yahoo Finance
CureVac (NASDAQ:CVAC) Trading Up 7.5% – Should You Buy? - Defense World
CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript - Insider Monkey
CureVac N.V. Earnings Call: Financial Strength Amid Challenges - TipRanks
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode - MSN
CureVac NV earnings beat by €0.06, revenue topped estimates - Investing.com South Africa
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
CureVac: 2025 will be less costly - marketscreener.com
CureVac Announces Financial Results for the Fourth Quarter and F - GuruFocus
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience - Yahoo Finance
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience By GuruFocus - Investing.com Canada
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Pa - GuruFocus
CureVac Reports Strong 2024 Financial Results and Strategic Progress - TipRanks
CureVac Reports 2024 Financial Results and Strategic Advances - TipRanks
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update - ACCESS Newswire
CureVac Q4 2024 Earnings Call Transcript - MarketBeat
Insights Ahead: CureVac's Quarterly Earnings - Benzinga
CureVac to initiate Phase 1 trial for its lung cancer therapy - MSN
FDA clears CureVac’s IND application for Phase I lung cancer trial - MSN
FDA clears Curevac’s IND for CVHNLC - BioWorld MedTech
EQS-News: CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - sharewise.com
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - ACCESS Newswire
CureVac Financial Results: Key mRNA Biotech Player to Reveal 2024 Performance - Stock Titan
CureVac’s lung cancer therapy clears FDA hurdle - Investing.com Australia
CureVac’s lung cancer therapy clears FDA hurdle By Investing.com - Investing.com South Africa
CureVac's Early-stage Trial of Lung Cancer Drug Gets US FDA Clearance - MarketScreener
CureVac to initiate Phase 1 trial for its lung cancer therapy (CVAC:NASDAQ) - Seeking Alpha
CureVac Receives FDA Clearance to Initiate Phase 1 Trial of Lung Cancer Therapy - MarketScreener
EQS-News: CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - sharewise.com
4.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):